Patents by Inventor Daniel L. Dexter

Daniel L. Dexter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treating a tumor
    Patent number: 6319923
    Abstract: In accordance with the present invention there is provided a method of treating a mammal having a solid tumor, the method comprising: a) administering to the mammal an effective amount of 3-ainino-1,2,4-benzotriazine 1,4-dioxide; b) administering to the mammal an effective amount of paclitaxel; and c) administering to the mammal an effective amount of a platinum complex. The method provides unexpected synergistic efficacy. The invention further provides a kit for treatment of a mammalian tumor comprising 3-amino-1,2,-benzotriazine 1,4-dioxide, paclitaxel and a platinum complex.
    Type: Grant
    Filed: February 16, 2000
    Date of Patent: November 20, 2001
    Assignee: Sanofi-Synthelabo Inc.
    Inventors: Daniel L. Dexter, Paul E. Juniewicz, James B. Rake, Daniel D. Von Hoff
  • Method of treating a tumor
    Patent number: 6063780
    Abstract: In accordance with the present invention there is provided a method of treating a mammal having a solid tumor, the method comprising:a) administering to the mammal an effective amount of 3-amino-1,2,4-benzotriazine 1,4-dioxide;b) administering to the mammal an effective amount of paclitaxel; andc) administering to the mammal an effective amount of a platinum complex.The method provides unexpected synergistic efficacy. The invention further provides a kit for treatment of a mammalian tumor comprising 3-amino-1,2,-benzotriazine 1,4-dioxide, paclitaxel and a platinum complex.
    Type: Grant
    Filed: February 27, 1998
    Date of Patent: May 16, 2000
    Assignee: Sanofi-Synthelabo Inc.
    Inventors: Daniel L. Dexter, Paul E. Juniewicz, James B. Rake, Daniel D. Von Hoff
  • Unsymmetrically linked bisnaphthalimides as antitumor agents
    Patent number: 5604095
    Abstract: The present invention provides novel bis-naphthalimides characterized by having a linker containing a heteroatom, their preparation, pharmaceutical compositions thereof, and various methods of using the bis-naphthalimides. Particularly preferred bis-naphthalimides have a linker of about 8-16 atoms where the heteroatom is oxygen, sulfur, sulfur oxide or sulfur dioxide. The bis-naphthalimides provided herein have exceptional DNA binding properties and demonstrate cytotoxicity in both in vitro and in vivo tumor models, in particular, against melanoma.
    Type: Grant
    Filed: July 22, 1994
    Date of Patent: February 18, 1997
    Assignee: Cancer Therapy & Research Center
    Inventors: Alexander L. Weis, Shih-Fong Chen, Peech S. Reedy, Mallaiah Mittakanti, Daniel L. Dexter
  • Diamine platinum naphthalimide complexes as antitumor agents
    Patent number: 5561042
    Abstract: The present invention provides novel bis-naphthalimides characterized by having a linker containing a heteroatom, their preparation, pharmaceutical compositions thereof, and various methods of using the bis-naphthalimides. Particularly preferred bis-naphthalimides have a linker of about 8-16 atoms where the heteroatom is oxygen, sulfur, sulfur oxide or sulfur dioxide. The bis-naphthalimides provided herein have exceptional DNA binding properties and demonstrate cytotoxicity in both in vitro and in vivo tumor models, in particular, against melanoma. Also provided a novel mono-naphthalimides linked to a DNA alkylating agent. These agents are shown to have conformational effects on double stranded DNA and to form covalent adducts after an extended incubation period.
    Type: Grant
    Filed: January 30, 1995
    Date of Patent: October 1, 1996
    Assignee: Cancer Therapy and Research Center
    Inventors: Alexander L. Weis, Shih-Fong Chen, Peech S. Reddy, Mallaiah Mittakanti, Daniel L. Dexter, Jan M. Woynarowski